ライフサイエンスコーパス: transcatheter

1 lso underwent electroanatomic mapping and VA transcatheter ablation.

2 of patients in the United States undergoing transcatheter and surgical aortic valve replacement for

3 namic in the first year after self-expanding transcatheter and surgical aortic valve replacement, but

4 this study was to compare the durability of transcatheter and surgical bioprosthetic aortic valves u

5 history of this finding, differences between transcatheter and surgical valves, and its association w

6 r catheter-delivered valve implantation (eg, transcatheter aortic and mitral valve replacements) was

7 Transcatheter aortic and pulmonary valves have been used

8 The long-term assessment of transcatheter aortic bioprosthetic valves durability is

9 The durability of transcatheter aortic bioprosthetic valves is a crucial i

10 The SURTAVI trial (Surgical Replacement and Transcatheter Aortic Implantation) compared TAVR using a

11 Long-term transcatheter aortic valve function is excellent.

12 Transcatheter aortic valve implantation (TAVI) has emerg

13 Transcatheter aortic valve implantation (TAVI) has revol

14 Transcatheter aortic valve implantation (TAVI) has revol

15 Transcatheter aortic valve implantation (TAVI) still pre

16 intermediate coronary stenoses treated with transcatheter aortic valve implantation (TAVI) were incl

17 one of the most devastating complications of transcatheter aortic valve implantation (TAVI).

18 placement, and eight patients had successful transcatheter aortic valve implantation (TAVI).

19 The multicenter Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) regist

20 l Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03

21 ES <20 but were still considered appropriate transcatheter aortic valve implantation candidates by th

22 discrimination and calibration power in this transcatheter aortic valve implantation cohort.

23 try is to capture the sizing ratios used for transcatheter aortic valve implantation in BAV and analy

24 Transcatheter aortic valve implantation is increasingly

25 with BAV along with available pre- and post-transcatheter aortic valve implantation multidetector co

26 f SAPIEN 3 transcatheter heart valve treated transcatheter aortic valve implantation patients had a l

27 luded 353 consecutive patients who underwent transcatheter aortic valve implantation using new-genera

28 dent predictor of CSA in patients undergoing transcatheter aortic valve implantation without preexist

29 TAVI (United Kingdom Transcatheter Aortic Valve Implantation) registry.

30 alves and General Versus Local Anesthesia in Transcatheter Aortic Valve Implantation) trial is a mult

31 l Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial is an ong

32 (MAC) score on the development of CSA after transcatheter aortic valve implantation.

33 surgical aortic valve replacement and 4 redo-transcatheter aortic valve implantation.

34 Of 614 patients who underwent transcatheter aortic valve replacement (11.8% PPMI rate)

35 riable adjustment for age, sex, and surgical/transcatheter aortic valve replacement (as time-dependen

36 low-surgical-risk aortic stenosis to undergo transcatheter aortic valve replacement (n = 221) or surg

37 t of evidence supports the widespread use of transcatheter aortic valve replacement (TAVR) among pati

38 Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) and redo s

39 , left ventricular assist device (LVAD), and transcatheter aortic valve replacement (TAVR) are expens

40 Conduction disturbances after transcatheter aortic valve replacement (TAVR) are often

41 However, data on the risk of IE following transcatheter aortic valve replacement (TAVR) are sparse

42 ollected data on 276,316 patients undergoing transcatheter aortic valve replacement (TAVR) at sites i

43 About one-half of transcatheter aortic valve replacement (TAVR) candidates

44 Transcatheter aortic valve replacement (TAVR) for degene

45 manage cardiac conduction disturbances after transcatheter aortic valve replacement (TAVR) has been e

46 Transcatheter aortic valve replacement (TAVR) has emerge

47 Transcatheter aortic valve replacement (TAVR) has emerge

48 stenosis between 2008 and 2017, when use of transcatheter aortic valve replacement (TAVR) in older a

49 al studies have demonstrated the benefits of transcatheter aortic valve replacement (TAVR) in patient

50 The role of transcatheter aortic valve replacement (TAVR) in this hi

51 A patient-specific computer simulation of transcatheter aortic valve replacement (TAVR) in tricusp

52 Transcatheter aortic valve replacement (TAVR) is an alte

53 Transcatheter aortic valve replacement (TAVR) is increas

54 Recent clinical trial results showed that transcatheter aortic valve replacement (TAVR) is noninfe

55 Transcatheter aortic valve replacement (TAVR) is supplan

56 Transcatheter aortic valve replacement (TAVR) is the pre

57 Transcatheter aortic valve replacement (TAVR) offers ano

58 se of this study was to assess the effect of transcatheter aortic valve replacement (TAVR) on hospita

59 The effect of transcatheter aortic valve replacement (TAVR) on kidney

60 tomographic imaging 30 days and 1 year after transcatheter aortic valve replacement (TAVR) or surgery

61 Hepatologists often determine whether transcatheter aortic valve replacement (TAVR) or surgica

62 t intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgica

63 lity at 1 year is similar after transfemoral transcatheter aortic valve replacement (TAVR) or surgica

64 zation and then randomized to treatment with transcatheter aortic valve replacement (TAVR) or surgica

65 k patients with severe aortic stenosis given transcatheter aortic valve replacement (TAVR) or surgica

66 The optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) remains a

67 is (AS) at low surgical risk, treatment with transcatheter aortic valve replacement (TAVR) results in

68 Two competing transcatheter aortic valve replacement (TAVR) technologi

69 Restricting transcatheter aortic valve replacement (TAVR) to centers

70 ration approved expanding the indication for transcatheter aortic valve replacement (TAVR) to low-ris

71 ntervention (NOTION) was designed to compare transcatheter aortic valve replacement (TAVR) to surgica

72 Expanding the indication of transcatheter aortic valve replacement (TAVR) toward low

73 Transcatheter aortic valve replacement (TAVR) use is inc

74 arce data exist on coronary events following transcatheter aortic valve replacement (TAVR), and no st

75 s (THVs) may cause coronary occlusion during transcatheter aortic valve replacement (TAVR)-in-TAVR an

76 in patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR).

77 known about long-term valve durability after transcatheter aortic valve replacement (TAVR).

78 ctive endocarditis may affect patients after transcatheter aortic valve replacement (TAVR).

79 ntermediate and hs-Tn in patients undergoing transcatheter aortic valve replacement (TAVR).

80 ted with fewer hospitalizations 1 year after transcatheter aortic valve replacement (TAVR).

81 a well-described in-hospital complication of transcatheter aortic valve replacement (TAVR).

82 major clinical outcomes following successful transcatheter aortic valve replacement (TAVR).

83 ding a volume-outcomes relationship (VOR) in transcatheter aortic valve replacement (TAVR).

84 out cerebral embolic protection (CEP) during transcatheter aortic valve replacement (TAVR).

85 stroke is important to improve the safety of transcatheter aortic valve replacement (TAVR).

86 Femoral access is the gold standard for transcatheter aortic valve replacement (TAVR).

87 surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).

88 eart failure (HF) readmission is common post-transcatheter aortic valve replacement (TAVR).

89 f information on surgical explantation after transcatheter aortic valve replacement (TAVR).

90 has worse outcomes or results in futility of transcatheter aortic valve replacement (TAVR).

91 as been commonly used as secondary access in transcatheter aortic valve replacement (TAVR).

92 and exercise performance (EP) >=1 year after transcatheter aortic valve replacement (TAVR).

93 nts were compared across treatment arms (eg, transcatheter aortic valve replacement [TAVR] versus sur

94 ening (HALT) in low-risk patients undergoing transcatheter aortic valve replacement and assessed 1-ye

95 cific differences in older adults undergoing transcatheter aortic valve replacement and draws attenti

96 ortality and acute kidney injury early after transcatheter aortic valve replacement and is an indepen

97 ears old with an indication for transfemoral transcatheter aortic valve replacement as agreed by the

98 ramipril or control groups after successful transcatheter aortic valve replacement at 14 centers in

99 Overall, 34 893 patients undergoing transcatheter aortic valve replacement at 445 hospitals

100 ding complications were commonly reported in transcatheter aortic valve replacement clinical trials.

101 with aortic stenosis undergoing transfemoral transcatheter aortic valve replacement comparing CS vers

102 nt the pathophysiological mechanisms of post-transcatheter aortic valve replacement complications and

103 ropensity-matched patients who had undergone transcatheter aortic valve replacement for aortic stenos

104 adequately assess the efficacy and safety of transcatheter aortic valve replacement for bicuspid aort

105 y Registry, we evaluated patients undergoing transcatheter aortic valve replacement from November 1,

106 valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducte

107 More recently, transcatheter aortic valve replacement has emerged as a

108 nd 2017, the rate of 30-day stroke following transcatheter aortic valve replacement in a US registry

109 l High Risk) and SURTAVI trials (Surgical or Transcatheter Aortic Valve Replacement in Intermediate-R

110 (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patie

111 tients with nonvalvular atrial fibrillation; transcatheter aortic valve replacement in patients with

112 In patients undergoing transcatheter aortic valve replacement in the US, vascul

113 52 medical centres experienced in performing transcatheter aortic valve replacement in the USA and Au

114 risk of patients with AS and concomitant CA, transcatheter aortic valve replacement may be preferred

115 This report suggests that transcatheter aortic valve replacement may favorably imp

116 The benefit of transcatheter aortic valve replacement on 12-month KCCQ

117 ive surgical risk, the estimated benefits of transcatheter aortic valve replacement on survival and h

118 (Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry; NCT0383

119 imal antithrombotic regimen after successful transcatheter aortic valve replacement remains unclear,

120 Echocardiography post-transcatheter aortic valve replacement showed a low mean

121 ts with large and extra-large aortic annuli, transcatheter aortic valve replacement using 29-mm Sapie

122 Placement of Aortic Transcatheter Valves) of transcatheter aortic valve replacement versus standard c

123 the 2-year rates of clinical events between transcatheter aortic valve replacement versus surgical a

124 At 12 months, the survival benefit of transcatheter aortic valve replacement was also greater

125 For the primary analysis cohort, transcatheter aortic valve replacement was performed in

126 transthoracic echocardiography pre- and post-transcatheter aortic valve replacement were considered e

127 c stenosis and large aortic annuli underwent transcatheter aortic valve replacement with 29-mm Sapien

128 risk cohort, and vascular access method, to transcatheter aortic valve replacement with the first ge

129 ibility, preliminary safety, and efficacy of transcatheter aortic valve replacement with the HLT Meri

130 Transcatheter aortic valve replacement with the Meridian

131 Transfemoral transcatheter aortic valve replacement with the self-exp

132 mized trials have compared bioprostheses for transcatheter aortic valve replacement, and no trials ha

133 After transcatheter aortic valve replacement, aortic flow was

134 arteriotomies created by current generation transcatheter aortic valve replacement, percutaneous end

135 icenter investigation in patients undergoing transcatheter aortic valve replacement, percutaneous end

136 osure devices have limitations when used for transcatheter aortic valve replacement, percutaneous end

137 astolic parameters is well established after transcatheter aortic valve replacement, the role of Tei

138 with aortic stenosis undergoing transfemoral transcatheter aortic valve replacement, use of CS compar

139 a large proportion of patients treated with transcatheter aortic valve replacement, yet there remain

140 formed in roughly 50% of patients undergoing transcatheter aortic valve replacement.

141 single right lung transplant 103 days after transcatheter aortic valve replacement.

142 gs suggest that CS can be safely applied for transcatheter aortic valve replacement.

143 mm(2) or >=94.2 mm) aortic annuli undergoing transcatheter aortic valve replacement.

144 f outcomes in older women and men undergoing transcatheter aortic valve replacement.

145 , is associated with the need for PPMI after transcatheter aortic valve replacement.

146 choice in this cohort of patients undergoing transcatheter aortic valve replacement.

147 ependent predictor of adverse outcomes after transcatheter aortic valve replacement.

148 uring short- and longer-term follow-up after transcatheter aortic valve replacement.

149 een systematically studied in the context of transcatheter aortic valve replacement.

150 End point was PPMI at 1 month after transcatheter aortic valve replacement.

151 association of AMCC and need for PPMI after transcatheter aortic valve replacement.

152 successfully bridged to lung transplant via transcatheter aortic valve replacement.

153 it of red blood cell (RBC) transfusion after transcatheter aortic valve replacement.

154 rwent a double lung transplant 56 days after transcatheter aortic valve replacement.

155 E neo and CoreValve Evolut bioprostheses for transcatheter aortic valve replacement.

156 ctively included patients after transfemoral transcatheter aortic valve replacement; propensity score

157 Transcatheter aortic valve replacements are minimally in

158 of the self-expanding intra-annular Portico transcatheter aortic valve system (Abbott Structural Hea

159 controlled trial (the Portico Re-sheathable Transcatheter Aortic Valve System US Investigational Dev

160 on alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not

161 on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patien

162 ith surgery, major outcomes are similar with transcatheter aortic-valve replacement (TAVR) and surgic

163 comes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compare

164 During the introduction of transcatheter aortic-valve replacement (TAVR) in the Uni

165 Transcatheter aortic-valve replacement (TAVR) is an alte

166 coagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not kno

167 aban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear

168 hen deciding on a case-by-case basis between transcatheter arterial embolization and surgery.

169 Efficacy and safety of selective transcatheter arterial embolization in three consecutive

170 Transcatheter arterial embolization is not an effective

171 BEST PRACTICE ADVICE 10: Prophylactic transcatheter arterial embolization of high-risk ulcers

172 temic and surgical treatments, radiotherapy, transcatheter arterial therapies, and portal vein revasc

173 ere excluded from the pivotal evaluations of transcatheter AV replacement (TAVR) devices.

174 early clinical case series, a novel therapy, transcatheter bariatric embolotherapy (TBE) of the left

175 have established the proof-of-principle that transcatheter bariatric embolotherapy of the left gastri

176 ical leaflet thrombosis was more frequent in transcatheter compared with surgical valves at 30 days,

177 Transcatheter correction of SVASD may be considered as a

178 Transcatheter correction was performed in 25 patients, w

179 Transcatheter electrosurgery already enables a range of

180 Transcatheter electrosurgery refers to a family of proce

181 Superselective transcatheter embolization has shown to be an effective

182 Minimally invasive transcatheter embolization is a common nonsurgical proce

183 Transcatheter embolization is a minimally invasive proce

184 35.8% in the surgical group and 48.3% in the transcatheter group (hazard ratio, 1.38; 95% CI, 1.12-1.

185 ve and to determine whether patient-specific transcatheter heart valve (THV) sizing and positioning m

186 eatment with the balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or witho

187 The dock and transcatheter heart valve form an ensemble, with the nat

188 The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients With Aort

189 valvular heart disease for many decades, but transcatheter heart valve therapy has revolutionized the

190 s real-world setting, two-thirds of SAPIEN 3 transcatheter heart valve treated transcatheter aortic v

191 ted with the commercially available SAPIEN 3 transcatheter heart valve.

192 chordae tendineae, and a balloon-expandable transcatheter heart valve.

193 ctancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited.

194 the self-expanding Evolut PRO or Evolut PRO+ transcatheter heart valves (THVs) may cause coronary occ

195 oon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end poin

196 theter mitral valve replacement using aortic transcatheter heart valves has recently become an altern

197 on self-expandable versus balloon-expandable transcatheter heart valves in bicuspid aortic stenosis a

198 ce of balloon-expandable and self-expandable transcatheter heart valves in the treatment of bicuspid

199 MViV using aortic balloon-expandable transcatheter heart valves is associated with a low comp

200 espite the tremendous technical evolution of transcatheter heart valves, to date, the clinically avai

201 Background Postoperative transcatheter interventions (TCIs) are performed after c

202 gnificant proportion of lesions treated with transcatheter interventions in the coronary arteries, mo

203 t to prevent LVOT obstruction (LAMPOON) is a transcatheter mimic of surgical chord-sparing leaflet re

204 Transcatheter mitral valve implantation (TMVI) is emergi

205 There has been an increase in focus on transcatheter mitral valve interventions, for both mitra

206 418 patients >65 years of age who underwent transcatheter mitral valve repair (MitraClip) for severe

207 Transcatheter mitral valve repair (TMVr) for the treatme

208 ulmonary hypertension influences outcomes of transcatheter mitral valve repair (TMVr) in patients wit

209 with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced

210 mitral regurgitation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet

211 r severe secondary mitral regurgitation with transcatheter mitral valve repair (TMVr) using the Mitra

212 s have demonstrated health status benefit of transcatheter mitral valve repair (TMVr) with MitraClip

213 egurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraC

214 With Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) with the MitraC

215 procedure, one-sixth of patients undergoing transcatheter mitral valve repair had AKI, linked to dev

216 patients with interventricular dyssynchrony, transcatheter mitral valve repair in patients with sever

217 idence on benefit-risk tradeoffs relevant to transcatheter mitral valve repair versus medical therapy

218 Transcatheter mitral valve repair with the MitraClip in

219 Transcatheter mitral valve repair with the MitraClip res

220 structures (eg, cardiac resynchronization or transcatheter mitral valve repair), but they may derive

221 ected only at the mitral valve leaflets (eg, transcatheter mitral valve repair).

222 ts include SGLT2 inhibitors, vericiguat, and transcatheter mitral valve repair, all of which incremen

223 long-term favorable clinical response after transcatheter mitral valve repair.

224 ns with patients who are being evaluated for transcatheter mitral valve repair.

225 Transcatheter mitral valve replacement (TMVR) is a rapid

226 he feasibility of a percutaneous transseptal transcatheter mitral valve replacement (TMVR) system.

227 eading cause of mortality and exclusion from transcatheter mitral valve replacement (TMVR).

228 this study was to evaluate the potential for transcatheter mitral valve replacement in patients with

229 Transcatheter mitral valve replacement in severe mitral

230 Transcatheter mitral valve replacement is a novel therap

231 leaflet (LAMPOON) is an effective adjunct to transcatheter mitral valve replacement that prevents lef

232 Transcatheter mitral valve replacement using aortic tran

233 Procedure times (from traversal to transcatheter mitral valve replacement) were shorter, co

234 tegy to lacerate the anterior leaflet before transcatheter mitral valve replacement.

235 mplantation of supra-annular, self-expanding transcatheter, or surgical bioprostheses.

236 ath, ischemic, hemorrhagic events) following transcatheter PFO closure.

237 ular and valvular heart disease are invasive transcatheter procedures or surgeries that do not fully

238 Transcatheter procedures were performed in 38.7% of pati

239 Given the rapid growth of large-bore transcatheter procedures, bleeding avoidance strategies

240 t valve replacement options, with a focus on transcatheter prostheses.

241 The Harmony transcatheter pulmonary valve (TPV) was designed for tre

242 Transcatheter pulmonary valve replacement (TPVR) is asso

243 imited published data focused on outcomes of transcatheter pulmonary valve replacement (TPVR) with ei

244 tral valve anatomy, an update on the current transcatheter repair and replacement therapies, as well

245 able heart valve prostheses for surgical and transcatheter replacement have considerable limitations.

246 used to predict the success of these future transcatheter solutions.

247 e, and represents a promising advance toward transcatheter surgery.

248 Icuspid Regurgitation RePAIr With CaRdioband Transcatheter System [TRI-REPAIR]; NCT02981953).

249 Icuspid Regurgitation RePAIr With CaRdioband Transcatheter System) study.

250 curate marker of the quality of surgical and transcatheter therapeutic interventions.

251 y, with regard to preprocedural planning for transcatheter therapies.

252 port the 6-month safety and performance of a transcatheter tricuspid valve reconstruction system in t

253 fectiveness of TriClip, a minimally invasive transcatheter tricuspid valve repair system, for reducin

254 termediate-term valve-related outcomes after transcatheter tricuspid valve replacement (TTVR), includ

255 Surgical explant of the transcatheter valve (SEV, 8.7%; BEV, 13.8%; P=0.21), and

256 However, the impact of transcatheter valve durability remains uncertain.

257 At a transcatheter valve failure time <30% compared with surg

258 onsortium-2', a definition routinely used in transcatheter valve implantation procedures.

259 Advanced imaging planning, new transcatheter valve platforms, procedure streamlining an

260 ctancy was <0.10 between TAVR and SAVR until transcatheter valve prosthesis failure time was 70% shor

261 ificant mitral regurgitation (MR) undergoing transcatheter valve repair with MitraClip.

262 tive capacity of potential tissue engineered transcatheter valve scaffolds (1) acellular porcine peri

263 s (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapies Registry from June 2015 to

264 acic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry from November 9,

265 S)/American College of Cardiology (ACC) TVT (Transcatheter Valve Therapies) registry, 3,053 (4.2%) pa

266 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (November 2011 thro

267 We analyzed data from the Transcatheter Valve Therapy Registry regarding procedura

268 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry were analyzed with

269 between November 2013 and March 2019 in the Transcatheter Valve Therapy Registry were included.

270 acic Surgeons-American College of Cardiology Transcatheter Valve Therapy Registry) from 2011 to 2019

271 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, we evaluated patie

272 acic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry.

273 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.

274 Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) registry with linkage to Me

275 R trials and registries (Placement of Aortic Transcatheter Valve).

276 s, and they were treated successfully with a transcatheter valve-in-valve procedure (Melody TPV).

277 (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII A [PARTNERII A]; NCT01314313;

278 in the PARTNER 2 trial (Placement of Aortic Transcatheter Valves 2).

279 (Placement of AoRTic TraNscathetER Valves [PARTNERII A]; NCT01314313).

280 While most self-expanding transcatheter valves are repositionable, only one fully

281 22128; PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry

282 (The PARTNER II Trial: Placement of Aortic Transcatheter Valves II - PARTNER II - Nested Registry 3

283 3; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 In

284 (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 In

285 It is unknown whether transcatheter valves will have similar durability as sur

286 ing TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) 1, 2, and PARTNER 2 S3 trials betw

287 ograms from the PARTNER (Placement of Aortic Transcatheter Valves) 2 SAPIEN 3 registry were analyzed

288 the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 valve-in-valve and continued acc

289 t (SAVR) in the PARTNER (Placement of Aortic Transcatheter Valves) 2A trial and registry.

290 the PARTNER 2 trial (The Placement of Aortic Transcatheter Valves) and registry the outcomes after ao

291 ved TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) I, II, and S3 trials or registries

292 om the PARTNER 1B trial (Placement of Aortic Transcatheter Valves) of transcatheter aortic valve repl

293 The PARTNER 3 trial (Placement of Aortic Transcatheter Valves) randomized 1000 patients with seve

294 urgery in the PARTNER 3 (Placement of Aortic Transcatheter Valves) trial.

295 Currently, 2 third-generation transcatheter valves, 29-mm Sapien-3 and 34-mm Evolut-R

296 ed superiority (PARTNER [Placement of Aortic Transcatheter Valves] 3) or noninferiority (Evolut Low R

297 Transcatheter ventricular septal defect (VSD) closure is

298 HALT was more frequent in transcatheter versus surgical valves at 30 days (13% vs.

299 rcise test and echocardiography 1 day before transcatheter VSD closure and 6 months after interventio

300 Compared with conservative management, transcatheter VSD closure prevents deterioration in exer